REXULTI® (Brexpiprazole) FDA Approved for Treating Agitation in Alzheimer's Disease Patients
Por um escritor misterioso
Descrição
REXULTI® (brexpiprazole) has been approved by the FDA for treating agitation associated with dementia due to Alzheimer's disease, making it the first and only pharmacological treatment for this indication in the US.
FDA advisers back Lundbeck and Otsuka's Rexulti in Alzheimer's
Antipsychotic Drug Reduces Alzheimer's-Associated Agitation
Dementia: FDA fast-tracks approval for antipsychotic drug Rexulti
Otsuka and Lundbeck Issue Statement on REXULTI for Alzheimer's
Lundbeck, Otsuka drug cut agitation in Alzheimer's patients
Important News for Older Adults: FDA Approves First Drug to Treat
FDA Approves First-Ever Drug for Agitation Associated with
Researcher finds help for Alzheimer's-associated agitation with
FDA Accepts sNDA for Rexulti for Alzheimer's Agitation
de
por adulto (o preço varia de acordo com o tamanho do grupo)
